The hereditary angioedema market continues to evolve rapidly, influenced by significant advancements in treatment options and expanded patient diagnosis. The increasing industry size, fueled by expanding market opportunities and focused research efforts, fosters substantial business growth across geographies.
Market Size and Overview
The global hereditary angioedema market size is estimated to be valued at USD 3.13 billion in 2025 and is expected to reach USD 5.96 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 9.6% during the forecast period from 2025 to 2032.
Hereditary Angioedema Market Growth is driven by rising patient awareness, increased clinical adoption of novel therapies, and favorable regulatory approvals. The hereditary angioedema market report highlights expanding market revenue streams, alongside challenges such as treatment accessibility and diagnosis delays, which market players continue to address through dedicated market strategies.
Key Takeaways
- Dominating Region: North America holds a leading position in the hereditary angioedema market share in 2025, supported by strong healthcare infrastructure and significant investments in research and development.
- Fastest Growing Region: Asia Pacific is emerging as the fastest-growing market region, driven by increasing disease awareness and improving healthcare access. In Japan, approval of new hereditary angioedema treatments in 2024 has accelerated market revenue growth.
- By Product Type Segment:
- Dominant Sub-segment: Plasma-derived C1 inhibitors dominate product sales as established standard care.
- Fastest Growing Sub-segment: Recombinant C1 inhibitors are witnessing rapid market growth, exemplified by the launch of a recombinant therapy in the US market in 2025, enhancing treatment options.
- By Route of Administration Segment:
- Dominant Sub-segment: Intravenous administration remains key due to existing treatment protocols.
- Fastest Growing Sub-segment: Subcutaneous injections are gaining traction after a successful market introduction in Europe in 2024, boosting patients' adherence and market revenue.
- By Indication Segment:
- Dominant Sub-segment: Acute hereditary angioedema attacks remain the primary treatment focus.
- Fastest Growing Sub-segment: Prophylactic treatment is expanding rapidly with increasing adoption of longer-acting therapeutics demonstrated in clinical trials reported during 2025.
Market Key Trends
A significant trend shaping the hereditary angioedema market dynamics is the accelerating shift toward self-administered subcutaneous therapies. In 2024, multiple product launches of self-injectable drugs received regulatory approvals, reflecting strong market demand for improved patient convenience and compliance. For instance, recent innovations in recombinant C1 esterase inhibitors have revolutionized treatment protocols, enabling easier administration outside clinical settings. This development is expected to increase market share for new formulations, bolster hereditary angioedema market revenue, and open new market opportunities. Moreover, reimbursement expansions in key regions have reduced market restraints, enabling more patients to access these new therapies. This trend directly drives the hereditary angioedema market forecast's optimistic outlook, with anticipated higher growth rates sustained through 2032.
Key Players
Notable hereditary angioedema market players include CSL Behring, Sanofi, and Takeda Pharmaceutical, among others such as Pharming Group, Shire, and BioCryst Pharmaceuticals. These market companies are actively adopting growth strategies like strategic partnerships, innovation in biologics, and geographic expansions. For example, in 2025, CSL Behring expanded its manufacturing capacities to meet rising market demand, which translated into increased hereditary angioedema market revenue. Sanofi launched a novel oral HAE therapy in the European market in late 2024, enhancing its market position significantly. Takeda Pharmaceutical's recent collaboration with global research organizations has accelerated pipeline development, strengthening competitive positioning in evolving hereditary angioedema market dynamics. Collectively, these initiatives reinforce the competitive intensity and ongoing market growth trajectory observed in the market report.
FAQs
Q1: Who are the dominant players in the hereditary angioedema market?
The hereditary angioedema market is led by several key players, including CSL Behring, Sanofi, and Takeda Pharmaceutical, who continue to innovate and expand their therapeutic portfolios.
Q2: What will be the size of the hereditary angioedema market in the coming years?
The hereditary angioedema market size is projected to grow from USD 3.13 billion in 2025 to approximately USD 5.96 billion by 2032, with a CAGR of 9.6% during this period.
Q3: Which product type segment shows the largest growth opportunity in this market?
Recombinant C1 inhibitors represent the fastest-growing segment, with recent product approvals highlighting their expanding adoption globally.
Q4: How will market development trends evolve over the next five years?
The growing preference for subcutaneous self-administration therapies and increasing reimbursement coverage are key trends expected to drive substantial hereditary angioedema market growth and shape future market opportunities.
Q5: What is the nature of the competitive landscape and challenges in the hereditary angioedema market?
The market is highly competitive with key players focusing on innovation and partnerships. Challenges include treatment affordability and late diagnosis, which are being addressed through improved market strategies and patient awareness campaigns.
Q6: What go-to-market strategies are commonly adopted in the hereditary angioedema market?
Companies in the hereditary angioedema market utilize strategic collaborations, regional expansions, and product innovation to capture market share and enhance market revenue, as evidenced by recent launches and capacity expansions in 2024 and 2025.
Get This Report in Japanese Language - 遺伝性血管性浮腫市場
Get This Report in Korean Language –유전성 혈관부종 시장
Read More Articles Related to this Industry -
Role of Generic Drugs in the Saudi Arabia Pharmaceutical Drugs Market
Technological Advancements in Saudi Arabia Pharmaceutical Drugs Industry
Recent Developments in Saudi Arabia Pharmaceutical Drugs Industry
About Author:
Priya Pandey is a dynamic and passionate editor with over three years of expertise in content editing and proofreading. Holding a bachelor's degree in biotechnology, Priya has a knack for making the content engaging. Her diverse portfolio includes editing documents across different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. Priya's meticulous attention to detail and commitment to excellence make her an invaluable asset in the world of content creation and refinement.
(LinkedIn- https://www.linkedin.com/in/priya-pandey-8417a8173/)
